#DMmr
🔎 Scientists investigated the immune architecture associated with anti–PD-1 response in #ColorectalCancer and features that could be therapeutically induced in mismatch repair-proficient tumors.

Read more about their work in @science.org ➡️ https://bit.ly/3Xd4Dgp
November 18, 2026 at 12:06 AM
🧬 Open‑access study shows how spatial immune architecture and macrophage polarization shape immunotherapy responses in mismatch repair–deficient colorectal cancer, helping explain why metastatic lesions respond differently.

👉 vist.ly/5smy3

#Immunotherapy
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
AbstractIntroduction. Mismatch repair-deficient (dMMR) colorectal cancers (CRCs) exhibit variable clinical responses to immune checkpoint inhibitors (ICIs)
doi.org
November 13, 2026 at 12:00 PM
Cancer de l’endomètre : deux essais majeurs à l’ESMO 2026
KEYNOTE-C93 et TroFuse-005 évaluent 2 stratégies : le pembrolizumab en monothérapie en 1ère ligne dMMR et le sacituzumab tirumotecan après traitement. Analyse de Dre Diana Bello Roufai (Institut Curie).
https://mdsc.pe/4Apo5Vw
Cancer de l’endomètre : deux essais majeurs à l’ESMO 2026
À l’ESMO 2026, KEYNOTE-C93 et TroFuse-005 évaluent deux stratégies dans le cancer de l’endomètre : le pembrolizumab en monothérapie en première ligne dMMR et le sacituzumab tirumotecan après traitement.
francais.medscape.com
November 13, 2026 at 8:25 PM
Your experience can help shape cancer treatment decisions in Canada. Diagnosed with (or caring for someone with) MSI-H/dMMR Stage II/III locally advanced rectal cancer? Join a Zoom interview to inform our patient input submission to CDA-AMC. Contact us to learn more.
November 13, 2026 at 8:03 PM
FDA grants accelerated approval to GSK's Jemperli (dostarlimab) in stage II–III MSI-H/dMMR locally advanced rectal cancer. Phase 2 AZUR-1: 68% (98/144) sustained clinical complete response at 12 months by investigator; central review still maturing (47%). https://inlightbio.com/news/?type=policy
November 13, 2026 at 12:45 PM
Votre expérience peut façonner les décisions sur les traitements du cancer au Canada. Cancer du rectum localement avancé de stade II/III IMS-E/dMMR, pour vous ou un proche? Participez à une entrevue Zoom pour nourrir notre soumission à l’Agence des médicaments du Canada (CDA-AMC)
November 13, 2026 at 8:05 PM
🗓️ October GI cancer news included FDA approvals for dMMR CRC, designations and international regulatory actions, data from #ESMO2026, and expert perspectives on immunotherapy and MEK inhibition. #crcsm #oncology

Sign up to read the full recap ➡️! www.onclive.com/view/gi-canc...
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in October 2026 | OncLive
Check out this October recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
www.onclive.com
November 12, 2026 at 1:53 PM
Neoadjuvant botensilimab plus balstilimab triggers significant pathological responses in early-stage colon cancer, potentially broadening immunotherapy benefit…

by Ghelardi F, Ambrosini M (...) Pietrantonio F et 51 al. in Nat Med #MedSky

👉 get more here

📖 read the article:
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial - Nature Medicine
In the phase 2 UNICORN trial, a short course of neoadjuvant botensilimab and balstilimab achieved the primary endpoint of pathological major response rate in patients with pMMR or dMMR colon cancer.
www.nature.com
November 11, 2026 at 1:47 PM
Pembrolizumab improves progression-free survival but misses overall survival target in dMMR endometrial cancer interim analysis.
Pembrolizumab improves progression-free survival but misses overall survival target in dMMR endometrial cancer
Pembrolizumab improves progression-free survival but misses overall survival target in dMMR endometrial cancer interim analysis. First-line pembrolizumab showed a statistically significant and clinically meaningful improvement in progression-free survival, with lower frequency of overall and grade 3 or above treatment-related adverse events. Randomised trial, Lancet, 26 Oct 2026.
enclai.net
November 5, 2026 at 2:30 AM
Cercek (@mskcancercenter.bsky.social) believes that physicians will have to grow more comfortable with non-operative management of dMMR locally advanced rectal cancer patients.
https://cancerletter.com/clinical/20261030_3/
MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care - The Cancer Letter
Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untrea
cancerletter.com
November 4, 2026 at 3:00 PM
Pembrolizumab Outperforms Carboplatin-Paclitaxel, Offering Significant Progression-Free Survival Gains in dMMR Endometrial Cancer

by Slomovitz BM, Zhu J (...) Pignata S et 26 al. in Lancet #MedSky

👉 get more here

📖 read the article: here
November 4, 2026 at 3:47 PM
The @fda.gov has approved atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin chemotherapy for the adjuvant treatment of patients with Stage III mismatch repair-deficient (dMMR) colon cancer.
Link in the comments 👇

#Atezolizumab #Immunotherapy #Oncology
November 4, 2026 at 2:47 AM
Dostarlimab monotherapy achieves 68% clinical complete response in previously untreated dMMR/MSI-H locally advanced rectal cancer, redefining treatment potential.

by Cercek A, Bachet JB (...) Roodhart JML et 32 al. in Ann Oncol #MedSky

👉 get more here

📖 read the article: here
November 3, 2026 at 9:47 AM
Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial
The cohort-specific design and an overview of screening and enrollment flows are reported in Fig. 1a and Fig. 1b, respectively. From June 2023 to July 2024, 56 patients with radiologically staged rT3−4 N0/N+ M0, resectable pMMR or dMMR colon adenocarcinoma were enrolled in cohorts 4 (pMMR BOT), 5 (pMMR BOT + BAL), 6 (dMMR BOT) and 7 (dMMR BOT + BAL) of UNICORN. Twenty-eight patients with pMMR CC were sequentially enrolled in BOT (n = 14) or BOT + BAL (n = 14) cohorts; 28 patients with dMMR CC were enrolled in BOT (n = 14) and, subsequently, BOT + BAL (n = 14) cohorts. The pMMR BOT cohort enrolled patients from 28 June 2023 to 1 January 2024; the pMMR BOT + BAL cohort enrolled patients from 10 January to 2 May 2024; the dMMR BOT cohort enrolled patients from 24 July 2023 to 14 February 2024; and the dMMR BOT + BAL cohort enrolled patients from 29 February to 24 July 2024. The data cutoff date for the present analyses was 9 February 2026. Baseline patient and disease characteristics are reported in Table 1. In brief, patient demographics and tumor features were in line with literature data, with...
www.nature.com
November 2, 2026 at 5:13 PM
🧬 Can dual checkpoint inhibition redefine the treatment landscape in MSI-H/dMMR metastatic colorectal cancer?

www.annalsofoncology.org/article/S092...

📊 Final CheckMate 8HW results demonstrate:
🔹 OS benefit vs nivolumab across all treatment lines
🔹 OS benefit vs chemotherapy in 1L (HR 0.37)
November 2, 2026 at 1:29 PM
Andrea Cercek (@mskcancercenter.bsky.social): "If 10 out of the 13 that went to surgery had no tumors left, it is very likely that a large proportion that went straight to radiation or straight to chemotherapy also had no tumors left."
https://cancerletter.com/clinical/20261030_3/
MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care - The Cancer Letter
Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untrea
cancerletter.com
November 2, 2026 at 4:15 PM
GSK has announced that it has secured U.S. approval for dostarlimab (Jemperli) as the first and only immunotherapy for adults with stage II or III microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) locally advanced rectal cancer.

See more👇
thepharmanavigator.com/news/gsk-win...
GSK Wins FDA Approval for its Locally Advanced Rectal Cancer Immunotherapy - The Pharma Navigator
The accelerated approval of dostarlimab (Jemperli) could allow eligible patients with biomarker-defined rectal cancer to avoid chemotherapy, radiotherapy, and surgery.
thepharmanavigator.com
November 2, 2026 at 1:32 PM
MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care
https://cancerletter.com/clinical/20261030_3/
MSK’s Andrea Cercek: Oncology faces learning curve as dostarlimab challenges dMMR rectal cancer standard of care - The Cancer Letter
Earlier this week, FDA granted an accelerated approval to dostarlimab-gxly (Jemperli), for adults with previously untrea
cancerletter.com
October 31, 2026 at 2:01 PM
Sara Lonardi, MD, discusses the final OS analysis of #CheckMate8HW from #ESMO26 and why nivolumab/ipilimumab should be offered to nearly all patients with MSI-H/dMMR mCRC. Read the full interview from Targeted Onc: www.targetedonc.com/view/lonardi...
October 31, 2026 at 9:24 PM
Neoadjuvant immunotherapy with ipilimumab and nivolumab delivers 100% disease-free and overall survival in advanced dMMR colon cancer patients.

by Chalabi M, van den Dungen LDW (...) Haanen JBAG et 20 al. in Lancet #MedSky

👉 get more here

📖 read the article: here
October 30, 2026 at 5:47 PM
Manche Rektumkrebspatienten mit bestimmten Tumormerkmalen könnten auf Chemo, Bestrahlung und OP verzichten: Die FDA hat eine Immuntherapie beschleunigt zugelassen.
FDA lässt Dostarlimab bei Rektumkarzinom-Subtyp zu
Die US-Arzneimittelbehörde FDA hat Dostarlimab (Jemperli) beschleunigt für Erwachsene mit lokal fortgeschrittenem Rektumkarzinom im Stadium II/III mit durch einen von der FDA autorisierten Test nachgewiesenem MSI-H- oder dMMR-Status zugelassen, was m
denkstrom.org
October 29, 2026 at 6:16 PM
Single-agent immunotherapy as first-line treatment led to a huge improvement in PFS in inoperable recurrent/advanced mismatch repair-deficient endometrial cancer, a large randomized trial showed. #ESMO26
https://www.medpagetoday.com/meetingcoverage/esmo/123637
Chemo-Free First-Line Treatment Yields Huge PFS Gain in dMMR Endometrial Cancer
Pembrolizumab topped chemotherapy in trial that did not compare current standards of care
www.medpagetoday.com
October 29, 2026 at 6:02 PM
Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. www.sciencedirect.com/science/arti... #hvhebron #onco [Text complet]
www.sciencedirect.com
October 29, 2026 at 10:21 AM
📣 Scientific Publication of the Week 💡

This paper by M. Chalabi, L.D.W. van den Dungen, P.G.M. de Gooyer, ... & J.B.A.G. Haanen has been voted as our Scientific Publication of week 43

www.thelancet.com/journals/lan...
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
In patients with locally advanced dMMR colon cancer, treatment with ipilimumab and nivolumab before surgery resulted in a 3-year disease-free survival and 5-year overall survival of 100%. These findin...
www.thelancet.com
October 29, 2026 at 12:54 PM